Targeting the STAMBPL1/AXL axis significantly enhances the efficacy of sunitinib treatment and immunotherapy, hence it is worth exploring whether STAMPBP1 expression is associated with the prognosis in patients with renal cancer. Here, STAMBPL1 is linked to renal carcinoma.